AGM Statement

12 June 2013 Source BioScience plc (`Source BioScience', the `Group') ANNUAL GENERAL MEETING STATEMENT Laurie Turnbull, Chairman of Source BioScience, will be making the followingcomments at the 2013 Annual General Meeting to be held today at 10.30am: "Since our last AGM twelve months ago, we have been able to report another yearof growth and increased profitability for Source BioScience. The recentlyissued Interim Management Statement confirmed another good start to this yearas it was in 2012. Healthcare Demand from the NHS for our Diagnostic services continues to be strong and yearto date revenue has increased by over 35% compared with the same period lastyear. We remain one of only a small number of accredited laboratories in Europewith access to the technologies and expertise required to deliver complexgene-based diagnostic testing for cancer and other diseases, which affords uscommercial advantage. Implementation of our BD FocalPointTM automated imaging solution for cervicalcancer screening is progressing well. Currently, a total of seven BDFocalPointTM platforms are placed within the NHS, with a number of other NHSTrusts in discussion with Source BioScience about adopting the technology. In April we acquired Inverclyde Biologicals, based in Motherwell, Scotland andintegration is underway. The complementary range of serology products anddiagnostic testing kits accessible as a result of this acquisition furtherenhances our existing Healthcare products business. LifeSciences We enjoy a leading position in the UK for the provision of DNA sequencingservices and remain the only company offering a UK-based sequencing service.This part of our business will be boosted by the expansion of our service intoScotland, enabling us to offer our Overnight Service for DNA sequencing to thelocal research community. We are experiencing good uptake of the reSourceTM range of own branded productslaunched in March and we will be able to increase significantly the addressablemarket for our portfolio. Migration of the remainder of our LifeSciencesproducts to this branding is underway and all products will be availablethrough GenomeCube®. Outlook Results for the year ended 31 December 2012 demonstrated another good year ofgrowth for the business and trading for the early part of 2013 reflects theopportunities the Board has identified across both Healthcare and LifeSciences. We look forward to updating shareholders further following the publication ofour Half Year Report for the six months ending 30 June 2013, anticipated to bereleased in August as in previous years." --- ENDS --- For further information, please contact: Source BioScience plc Dr Nick Ash, CEO Tel: +44 (0) 115 973 9010 Email: [email protected] www.sourcebioscience.com For investor and media enquiries: N+1 Singer (Financial Advisor, Sponsor and Broker) Aubrey Powell/Joe Stroud Tel: +44 (0)203 201 3710 www.nplus1singer.com College Hill (PR Agency to Source BioScience) Melanie Toyne-Sewell/Stefanie Bacher Tel: +44 (0)207 457 2020 Mob: +44 (0) 7792 693760 Email: [email protected] About Source BioScience: Source BioScience plc (LSE: SBS) is an international diagnostics and geneticanalysis business serving the healthcare and research markets. The LifeSciencesdivision provides core laboratory research support from conceptualisation toimplementation, calling upon a wide range of cutting-edge technology platformsincluding an online catalogue of biomolecular tools. The Group is a trustedprovider of a complete range of sophisticated microarray, next generation andconventional sequencing services. GLP, GCP and CPA accreditations make thesequencing offerings also very attractive for applications in regulatorystudies or clinical settings. Its Healthcare operations provide screening andreference laboratory diagnostic testing for cancer and other diseases inaddition to complementary products for serology and diagnostic applications.The Group has its headquarters in Nottingham, UK. Further information aboutSource BioScience can be found at www.sourcebioscience.com